Boston Scientific Corp. (BSX:US)’s Watchman device to prevent strokes may face a contentious regulatory meeting this week after a U.S. report showed the surgery required to implant the product may reduce its effectiveness. The Watchman implant failed in a new trial to block clots in the heart’s left atrial appendage from causing a stroke as well as the current standard treatment that uses the blood-thinner warfarin, Food and Drug Administration staff said in a report today. Advisers to the agency are scheduled to meet Dec. 11 to weigh Watchman’s risks and benefits.
Help employers find you! Check out all the jobs and post your resume.
